Role of PTEN and MMP-7 expression in growth, invasion, metastasis and angiogenesis of gastric carcinoma

Pathology International

Volumn 53, Issue 10, 2003, Pages 659-666

  Zheng, Hua Chuan ^a   Sun, Jin Min ^a   Li, Xiao Han ^a   Yang, Xue Fei ^a   Zhang, Yin Chang ^a   Xin, Yan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Matrix metalloproteinase 7; Progression; PTEN; Stomach neoplasms; Tumorigenesis

Indexed keywords

MATRILYSIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STOMACH CARCINOMA; TUMOR CLASSIFICATION; TUMOR VOLUME; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 7; MICROCIRCULATION; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0344014119     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2003.01542.x     Document Type: Article

References (44)

1. Steck PA, Pershouse MA, Jasser SA et al. Identification of candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356-62.
2. Gu J, Tamura M, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-ativated protein (MAP) kinase signaling pathways. J Cell Biol 1998; 143: 1375-83.
3. Tamura M, Gu J, Takino T, Yamada KM. Tumor suppressor PTEN inhibition of cell invasion, migration and growth, differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999; 59: 442-9.
4. Tamura M, Gu J, Tran H, Yamada KM. PTEN gene and integrin signaling in cancer. J Natl Cancer Inst 1999; 91: 1820-28.
5. Maehama T, Dixon E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Cell Biol 1998; 273: 13375-8.
6. Hopkin, K. A surprising function for the PTEN tumor suppressor. Science 1998; 282: 1027-30.
7. Cantley LC, Neel BG. New insight into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 240-45.
8. Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
9. Knox JD, Boreham DR, Walker JA et al. Mapping of the metalloproteinase gene matrilysin (MMP7) to human chromosome 11q21-q22. Cytogenet Cell Genet 1996; 72: 179-82.
10. Adachi Y, Yamamoto H, Itoh F et al. Clinicopathologic and prognostic significance of matrilysin expression at the invasive front in human colorectal cancers. Int J Cancer 2001; 95: 290-94.
11. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas. J Clin Invest 2002; 109: 1437-44.
12. Nishizuka I, Ichikawa Y, Ishikawa T et al. Matrilysin stimulates DNA synthesis of cultured vascular endothelial cells and induces angiogenesis in vivo. Cancer Lett 2001; 173: 175-82.
13. Vargo-Gogola T, Fingleton B, Crawford HC, Matrisian LM. Matrilysin (matrix metalloproteinase-7) selects for apoptosis-resistant mammary cells in vivo. Cancer Res 2002; 62: 5559-63.
14. Cox G, O'Byrne KJ. Matrix metalloproteinases and cancer. Anticancer Res 2001; 21: 4207-19.
15. Davies G, Jiang WG, Mason MD. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res 2001; 7: 3289-97.
16. Yang L, Kuang LG, Zheng HC et al. PTEN-encoding product: a good molecular marker in tumorigenesis and progression of gastric cancer. World J Gastroenterol 2003; 9: 35-9.
17. Xin Y, Li XL, Wang YP et al. Relationship between phenotypes of cell-function differentiation and pathobiological behavior of gastric carcinomas. World J Gastroenterol 2001; 7: 53-9.
18. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995; 147: 9-19.
19. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.
20. Garcia JM, Silva JM, Dominguez G et al. Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 1999; 57: 237-43.
21. Lin WM, Forgacs E, Warshal DP et al. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res 1998; 4: 2577-83.
22. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002; 82: 285-91.
23. Zhou XP, Loukola A, Salovaara R et al. PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 2002; 161: 439-47.
24. Lee JI, Soria JC, Hassan KA et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 2001; 127: 1441-5.
25. Verma RS, Manikal M, Conte RA, Godec CJ. Chromosomal basis of adenocarcinoma of the prostate. Cancer Inves 1999; 17: 441-7.
26. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-6.
27. Rustia A, Wierzbicki V, Marrocco L, Tossini A, Zamponi C, Lista F. Is exon 5 of the PTEN/MMAC1 gene a prognostic marker in anaplastic glioma? Neurosurg Rev 2001; 24: 97-102.
28. Nozaki M, Tada M, Kobayashi H et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-Oncol 1999; 1: 124-37.
29. Minaguchi T, Yoshikawa H, Oda K et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 2001; 7: 2636-42.
30. Tada K, Shiraishi S, Kamiryo T et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 2001; 95: 651-9.
31. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 10031-3.
32. Maehama T, Taylor GS, Dixon JE. PTEN and myotubularin: novel phosphoinositide phosphatases. Annu Rev Biochem 2001; 70: 247-79.
33. Besson A, Robbins SM, Yong VW. PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis. Eur J Biochem 1999; 263: 605-11.
34. Waite KA, Eng C. Protean PTEN: form and function. Am J Hum Genet 2002; 70: 829-44.
35. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer 2001; 85: 383-92.
36. Adachi Y, Yamamoto H, Itoh F, Hinoda Y, Okada Y, Imai K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 1999; 45: 252-8.
37. Yamamoto H, Itoh F, Iku S et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001; 19: 1118-27.
38. Senota A, Itoh F, Yamamoto H, Adachi Y, Hinoda Y, Imai K. Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer. Clin Exp Metastasis 1998; 16: 313-21.
39. Park MJ, Kim MS, Park IC et al. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res 2002; 62: 6318-22.
40. Koul D, Parthasarathy R, Shen R et al. Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 2001; 20: 6669-78.
41. Giatromanolaki A, Koukourakis MI, Stathopoulos GP et al. Angiogenetic interactions of vascular endothelial growth factor of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res 2000; 12: 33-41.
42. Lu M, Jiang Y, Wang R. The relationship of vascular endothelial growth factor and angiogenesis to the progression of gastric carcinoma. Chin J Path 1998; 27: 278-81.
43. Huang J, Kontos CDPTEN. Modulates vascular endothelial growth factor-mediated signaling and angiogenetic effects. J Biol Chem 2002; 277: 10760-66.
44. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. J Arch Biochem Biophys 2002; 408: 155-61.